Literature DB >> 14644406

Post-heparin lipolytic enzyme activities, sex hormones and sex hormone-binding globulin (SHBG) in men and women: The HERITAGE Family Study.

A Desmeules1, C Couillard, A Tchernof, J Bergeron, T Rankinen, A S Leon, D C Rao, J S Skinner, J H Wilmore, J-P Després, C Bouchard.   

Abstract

We tested the hypothesis that androgen, estrogen, and sex hormone-binding globulin (SHBG) levels would be significantly related to post-heparin hepatic lipase (HL) and lipoprotein lipase (LPL) activities in a sample of Caucasian men (n = 233) and women (n = 235) aged 17-64 years from the HERITAGE Family Study. Body composition (hydrostatic weighing), abdominal adipose tissue distribution (computed tomography), plasma lipid-lipoprotein and hormone levels, and post-heparin lipases activities were measured. HL activity was significantly higher in males, whereas LPL activity was higher in women (P < 0.005). In women only, HL activity was positively associated with body fat mass (r = 0.17, P < 0.05) and intra-abdominal adipose tissue area (r = 0.18, P < 0.05). Significant associations were also found between fasting insulin and LPL activity (r = -0.16, P < 0.05 and r = -0.18, P < 0.005) as well as HL activity (r = 0.22, P < 0.005, and r = 0.27, P < 0.0001) in men and women, respectively. A positive association between total testosterone and HL activity was noted in men (r = 0.13, P = 0.05). In women, plasma SHBG levels were negatively associated with HL activity (r = -0.48, P < 0.0001), and statistical adjustment for body fat mass, visceral adipose tissue area, and fasting insulin did not attenuate this correlation. In multivariate analyses with models including adiposity variables and measurements of the hormonal profile, insulin, and testosterone levels were both independent positive predictors of HL activity in men. In women, hormone use was a significant positive predictor, and SHBG level a strong negative predictor of HL activity, independent of plasma estradiol and testosterone concentrations. Fasting insulin was the only significant predictor of LPL activity in men (negative association), whereas menstrual status, fasting insulin (negative associations), and plasma SHBG levels (positive association) were all independent predictors of LPL activity in women. These results suggest that the postulated sensitivity of lipolytic enzymes to androgens and estrogens is reflected by a strong negative association between SHBG levels and HL, and a lower magnitude positive association of this hormonal parameter to LPL activity in women. These associations appear to be independent from concomitant variation in total adiposity or body fat distribution. Copyright 2003 Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644406     DOI: 10.1016/j.atherosclerosis.2003.08.018

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  14 in total

1.  Changes in serum triglycerides and high-density lipoprotein concentration and composition after a low-fat mixed meal. Effects of gender and insulin resistance.

Authors:  Adriana Branchi; Adriana Torri; Cristina Berra; Emanuela Colombo; Domenico Sommariva
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

Review 2.  Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver.

Authors:  Gijs H Goossens; Johan W E Jocken; Ellen E Blaak
Journal:  Nat Rev Endocrinol       Date:  2020-11-10       Impact factor: 43.330

3.  Association of metabolic syndrome components with insulin resistance in normal weight population: the Qazvin Metabolic Diseases study.

Authors:  S Hashemipour; N Esmailzadehha; H Hamid; S Oveisi; P Yakhchaliha; A Ziaee
Journal:  J Endocrinol Invest       Date:  2015-05-08       Impact factor: 4.256

Review 4.  The HERITAGE Family Study: A Review of the Effects of Exercise Training on Cardiometabolic Health, with Insights into Molecular Transducers.

Authors:  Mark A Sarzynski; Treva K Rice; Jean-Pierre Després; Louis Pérusse; Angelo Tremblay; Philip R Stanforth; André Tchernof; Jacob L Barber; Francesco Falciani; Clary Clish; Jeremy M Robbins; Sujoy Ghosh; Robert E Gerszten; Arthur S Leon; James S Skinner; D C Rao; Claude Bouchard
Journal:  Med Sci Sports Exerc       Date:  2022-05-01

5.  Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men.

Authors:  Chaoyang Li; Earl S Ford; Benyi Li; Wayne H Giles; Simin Liu
Journal:  Diabetes Care       Date:  2010-04-05       Impact factor: 17.152

6.  Estrogen-enhanced gene expression of lipoprotein lipase in heart is antagonized by progesterone.

Authors:  Dianxin Liu; Anne Deschamps; Kenneth S Korach; Elizabeth Murphy
Journal:  Endocrinology       Date:  2007-11-01       Impact factor: 4.736

7.  LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study.

Authors:  Günther Silbernagel; Hubert Scharnagl; Marcus E Kleber; Graciela Delgado; Tatjana Stojakovic; Reijo Laaksonen; Jeanette Erdmann; Tuomo Rankinen; Claude Bouchard; Ulf Landmesser; Heribert Schunkert; Winfried März; Tanja B Grammer
Journal:  Atherosclerosis       Date:  2018-12-28       Impact factor: 5.162

Review 8.  Gender differences in skeletal muscle substrate metabolism - molecular mechanisms and insulin sensitivity.

Authors:  Anne-Marie Lundsgaard; Bente Kiens
Journal:  Front Endocrinol (Lausanne)       Date:  2014-11-13       Impact factor: 5.555

9.  Inverse Relationship between Hepatic Steatosis and Alanine Aminotransferase with Sex Hormone-Binding Globulin in Men.

Authors:  In Ho Seo; Hyung Bin Lee; Shinhye Kim; Yong Jae Lee; Dong Hyuk Jung
Journal:  Yonsei Med J       Date:  2017-07       Impact factor: 2.759

10.  Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner.

Authors:  E Theusch; K Kim; K Stevens; J D Smith; Y-D I Chen; J I Rotter; D A Nickerson; M W Medina
Journal:  Pharmacogenomics J       Date:  2016-03-01       Impact factor: 3.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.